Drug Detail

Drug Name Fluorouracil
Trade Name Adrucil
Synonyms 5-FU
Drug Descriptions

Adrucil (fluorouracil) is an antimetabolite chemotherapeutic agent, which interferes with DNA and RNA synthesis thereby preventing cancer cell growth (NCI Drug Dictionary). Fluorouracil is FDA approved for colorectal, breast, stomach, and pancreatic cancer (FDA.gov).

DrugClasses Chemotherapy - Antimetabolite 10

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Therapy Name Therapy Description
Fluorouracil + Irinotecan + Leucovorin + MM-151
fluorouracil + mitomycin
Pertuzumab + Trastuzumab + Fluorouracil + Epirubicin + Cyclophosphamide
Dasatinib + FOLFOX
Capecitabine + Fluorouracil + Talimogene laherparepvec + Oxaliplatin Imlygic (talimogene laherparepvec) is a GM-CSF expressing herpes simplex type-1 virus (HSV-1) that selectively infects and lyses tumor cells, and potentially induces a cytotoxic immune response against tumor cells (PMID: 25777572). Imlygic (talimogene laherparepvec) is FDA approved for use in patients with recurrent melanoma (FDA.gov).
Panitumumab + FOLFOX
Fluorouracil + Leucovorin + Irinotecan + Oxaliplatin + Saridegib
Trastuzumab + Fluorouracil + Leucovorin + Oxaliplatin
Bevacizumab + FOLFIRI + PCM-075 PCM-075 inhibits PLK1, resulting in cell cycle arrest and apoptosis in cancer cells (J Clin Oncol 36, 2018 (suppl 6S; abstr 369)).
FOLFIRINOX
Fluorouracil + Quinacrine + Sorafenib
CRLX101 + Fluorouracil + Radiotherapy
Fluorouracil + Cetuximab
FOLFIRI
PI-103 + 5-FU
FOLFOX + Nivolumab + Relatlimab
Methylnaltrexone + 5-FU
NANT triple negative breast cancer vaccine combination
Cetuximab + FOLFIRI
Binimetinib + FOLFIRI + Pembrolizumab
Lapatinib + Irinotecan + Leucovorin + Fluorouracil
Regorafenib + FOLFOX
ABT-165 + FOLFIRI
Aflibercept + Leucovorin + Fluorouracil
Fluorouracil + Irinotecan + Leucovorin + Rucaparib
Panitumumab + Oxaliplatin + Fluorouracil
PD0332991 + 5-FU
Bevacizumab + Fluorouracil + Leucovorin
Aflibercept + mFOLFOX-6
DT01 + Fluorouracil + Oxaliplatin
NANT colorectal cancer vaccine combination
Fluorouracil + Capecitabine + Irinotecan + Leucovorin + Oxaliplatin
BGJ398 + Fluorouracil + Irinotecan + Oxaliplatin
Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + Nivolumab
Nivolumab + Cisplatin + Fluorouacil
Palbociclib + Fluorouracil + Oxaliplatin
MN58b + Fluorouracil
Bevacizumab + MEDI4736 + Tremelimumab + FOLFOX
Fluorouracil + Leucovorin + Regorafenib
Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + NANT-008
Floxuridine + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Panitumumab
Cetuximab + Fluorouracil + NC-6004
Ad-CEA + Bevacizumab + FOLFOX
Bevacizumab + FOLFIRI
BGB-A317 + Cisplatin + Fluorouracil Tislelizumab (BGB-A317) is a human monoclonal antibody that targets PD-1 (PDCD1), thereby blocking the binding of PD-L1 (CD274) and potentially resulting in activation of a T-cell immune response against tumor cells (NCI Drug Dictionary).
Interferon alfa-2b + Fluorouracil
Cetuximab + FOLFIRI + Bevacizumab
NANT pancreatic cancer vaccine combination
Fluorouracil + Leucovorin
Cisplatin + Fluorouracil + Hydroxyurea
RO5520985 + Leucovorin + Fluorouracil
FOLFIRI + Pembrolizumab
Fluorouracil + Bevacizumab + Capecitabine + Leucovorin + Oxaliplatin
Axitinib + FOLFIRI
simtuzumab + FOLFIRI
BI 885578 + Fluorouracil
Binimetinib + FOLFIRI
CPI-613 + FOLFIRINOX
Nivolumab + mFOLFOX-6
Oleclumab + mFOLFOX
Fluorouracil + RU-A1
Fluorouracil + Leucovorin + Trastuzumab
Carboplatin + Fluorouracil + Paclitaxel + Vandetanib
Panitumumab + Oxaliplatin + Fluorouracil + Irinotecan
Bevacizumab + Fluorouracil + Irinotecan + Oxaliplatin
Onartuzumab + mFOLFOX6
FABLOx
NANT non-small cell lung cancer vaccine
Cetuximab + FOLFOX
Fluorouracil + Tanibirumab
mFOLFOX-6 + Pegilodecakin
mFOLFOX-6 + Tivozanib
Carboplatin + Cetuximab + Cisplatin + Fluorouracil
NANT hepatocellular carcinoma vaccine combination
Axitinib + FOLFOX
Durvalumab + Oleclumab + mFOLFOX
Cisplatin + Fluorouracil + Pembrolizumab + Trastuzumab
Capecitabine + Fluorouracil + Gemcitabine
MEK162 + FOLFOX
Bevacizumab + Cannabidiol + FOLFIRINOX
Floxiuridine + Panitumumab + Dexamethasone + FOLFIRI
CV301 + Nivolumab + mFOLFOX6
FOLFIRI + TRK-950 TRK-950 is a monoclonal antibody that targets a tumor associated antigen to induce immune mediated cytotoxicity of tumor cells (NCI Drug Dictionary).
Quinacrine + 5-fluorouracil
Fluorouracil + Epirubicin + Cyclophosphamide
INCB024360 + Nivolumab + mFOLFOX6
BMS-813160 + Fluorouracil + Irinotecan + Leucovorin
Cetuximab + ECF
Bevacizumab + FOLFOX
Floxuridine + Fluorouracil + Irinotecan
Panitumumab + FOLFIRI
Panitumumab + Fluorouracil + Leucovorin
FOLTAX
Gemcitabine + Nab-Paclitaxel + mFOLFOX-6
BGJ398 + Fluorouracil
mFOLFOX-6
Bevacizumab + FOLFIRINOX
Carboplatin + Cisplatin + Epacadostat + Fluorouracil + Nivolumab
FOLFIRINOX + Losartan
Ramucirumab + FOLFIRI
Cisplatin + Fluorouracil + Pembrolizumab
AZD9150 + Cisplatin + Durvalumab + Fluorouracil
Doxorubicin + Flourouracil + Cyclophosphamide
Necitumumab + FOLFOX
FOLFIRI + OMP-305B83
OBP-801 + 5-FU
Avelumab + Cisplatin + Fluorouracil + Mitomycin C
INCB001158 + FOLFOX
Cetuximab + Carboplatin + Fluorouracil
Dexamethasone + Diphenhydramine + Famotidine + 5FU + Hydroxyurea + Paclitaxel
Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab
Bevacizumab + FOLFOX + Nab-Rapamycin
Cetuximab + Cisplatin + Fluorouracil + Radiotherapy
Cetuximab + FOLFIRINOX
Atezolizumab + Fluorouracil + Oxaliplatin
FOLFIRINOX + Losartan + Nivolumab
Vandetanib + FOLFOX
Fluorouracil + Galunisertib
Carboplatin + Cisplatin + Fluorouracil + Nivolumab
Capecitabine + Fluorouracil + Cisplatin + Trastuzumab
Fluorouracil + OPB-31121
Fluoruracil + Leucovorin + Prexasertib
FOLFIRI + SYM004
Cabiralizumab + Fluorouracil + Irinotecan + Leucovorin + Nivolumab
Carboplatin + Fluorouracil
Sapitinib + Fluorouracil + Cisplatin
Cetuximab + Fluorouracil + Irinotecan + Floxuridine
mFOLFOX-6 + Atezolizumab + Cobimetinib
Fluorouracil + Oxaliplatin Eloxatin (oxaliplatin) is comprised of a platinum complex, which causes DNA-platinum cross-links, inhibition of DNA replication and transcription, and cell toxicity (NCI Drug Dictionary). Eloxatin (oxaliplatin) is FDA approved for colorectal cancer (FDA.gov).
Aflibercept + FOLFIRI
Bevacizumab + Fluorouracil + Oxaliplatin
Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab
Cetuximab + Cisplatin + Docetaxel + Fluorouracil
Dbait + Fluorouracil
FOLFIRINOX + Nivolumab
AB928 + mFOLFOX-6
Cisplatin + Fluorouracil + Trastuzumab
Bevacizumab + Docetaxel + Fluorouracil + Epirubicin + Cyclophosphamide
Trametinib + Fluorouracil
Bevacizumab + Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin
Fluorouracil
Ramucirumab + FOLFOX
Cetuximab + Dasatinib + FOLFOX
Cyclophosphamide + Fluorouracil + Docetaxel + Epirubicin
Cisplatin + Fluorouracil
mFOLFOX-6 + Atezolizumab
Cisplatin + Doxorubicin + Fluorouracil + Vincristine
FPA144 + Fluorouracil + Leucovorin + Oxaliplatin
Erlotinib + Fluorouracil + Leucovorin + nab-paclitaxel + Trastuzumab
Cisplatin + Docetaxel + Fluorouracil
Lapatinib + Oxaliplatin + Leucovorin + Fluorouracil
Fluorouracil + Irinotecan + Leucovorin + Nivolumab
Sorafenib + Fluorouracil
Claudiximab + FOLFOX
Fluorouacil + Ipilimumab + Nivolumab
Fluorouracil + Bevacizumab + Capecitabine + Irinotecan + Leucovorin
Dbait + Fluorouracil + Oxaliplatin
Cisplatin + Fluorouracil + Vincristine
E7046 + mFOLFOX-6
Capecitabine + Fluorouracil